Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT02954653
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Banner-University Medical Center Tucson, Tucson, Arizona, United States
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Target Recruit Count
- 60
- Registration Number
- NCT02937662
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Prescient Therapeutics, Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT02930109
- Locations
- 🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
- Conditions
- Acute Myeloid LeukemiaCore-Binding Factor
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 68
- Registration Number
- NCT02926586
- Locations
- 🇨🇳
Xianmin Song, Shanghai, Shanghai, China
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
- Conditions
- Mixed Phenotype Acute LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- Drug: CladribineDrug: CytarabineDrug: DecitabineBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Mitoxantrone Hydrochloride
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02921061
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
- Conditions
- AML
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02905994
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 6
- Registration Number
- NCT02891278
- Locations
- 🇺🇸
Johns Hopkins University Medical Center, Baltimore, Maryland, United States
🇺🇸Columbia University, New York, New York, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeB Acute Lymphoblastic LeukemiaCentral Nervous System LeukemiaTesticular Leukemia
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneDrug: EtoposideDrug: Doxorubicin HydrochlorideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine SulfateDrug: PrednisoneRadiation: Radiation Therapy
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- Drug: RituximabProcedure: Cranial irradiationDrug: NelarabineDrug: IdarubicinDrug: PEG-AsparaginaseDrug: ImatinibDrug: FludarabineDrug: DexamethasoneDrug: CyclophosphamideDrug: VincristineDrug: MethotrexateProcedure: Stem cell transplantationDrug: MercaptopurineDrug: CytarabineDrug: VP16Drug: VindesineDrug: Daunorubicin (DNR)Drug: AdriamycinDrug: Prednisolone
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.